Grufity logoGrufity logo

ARCT

16.46USD+0.03(+0.18%)Market Closed

Arcturus Therapeutics Holdings Inc.

Market Summary

USD16.46+0.03Market Closed
0.18%

ARCT Alerts

ARCT Stock Price

RSI Chart

Valuation

Market Cap

461.4M

Price/Earnings

-2.79

Price/Sales

11.37

Price/Cashflow

-3.18

MarketCap/EBT

-20.06

Price/Sales

Profitability

Return on Equity

-96.93%

Return on Assets

-49.1%

Fundamentals

Revenue

Revenue (TTM)

51.5M

Revenue Y/Y

448.58%

Revenue Q/Q

-50.66%

Earnings

Earnings (TTM)

-146.7M

Earnings Y/Y

34.79%

Earnings Q/Q

-63.55%

Price Action

52 Week Range

11.7048.75
(Low)(High)

Last 7 days

-5.9%

Last 30 days

10.6%

Last 90 days

-0.9%

Trailing 12 Months

-53.6%

Financial Health

Current Ratio

3.14

Debt/Equity

0.09

Debt/Cashflow

-9.48

Investor Care

Shares Dilution (1Y)

0.50%

Diluted EPS (TTM)

-5.56

Peers (Alternatives to Arcturus Therapeutics Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
5.63% 39.30%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
16.67% -47.75%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
-0.24% 13.25%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
1.82% 69.21%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
6.45% 11.40%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
20.16% 32.38%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
3.74% 44.64%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-10.14% 0.47%
-18.85
63.29
26.15% -23.38%
3.8B
-
51.28% -30.45%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
-7.43% -56.84%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-6.87% -55.08%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
21.64% 133.29%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
-5.25% -19.46%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
40.23% -67.39%
-1.4
4.57
-43.57% -69.06%
16.0M
-
-1.79% -86.93%
-0.46
19.11
-77.61% 5.14%

Financials for Arcturus Therapeutics Holdings

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue26.9%524115129
Operating Expenses-3.0%198205211215205
  S&GA Expenses3.8%4543424140
  R&D Expenses-4.8%153161169174165
Net Income11.4%-146.66-165.48-198.50-203.67-196.11
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-12.9%294337342393435
  Current Assets-15.4%247292327379421
    Cash Equivalents-16.2%238283320370414
  Net PPE26.8%119865
Liabilities-11.0%148166157165175
  Current Liabilities-18.2%7693107100118
  Long Term Debt-13.1%1315151515
    LT Debt, Current2.5%2827242218
    LT Debt, Non Current-10.4%3236394142
Shareholder's Equity-14.7%146171185228259
  Retained Earnings-8.4%-455.49-420.20-398.70-347.50-308.83
  Additional Paid-In Capital1.7%601591583576568
Accumulated Depreciation8.7%55444
Shares Outstanding0.2%2626262626
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-17.8%-170,763.00-145,010.00-141,132.00-135,043.00-99,178.00
  Share Based Compensation8.8%31,59929,03329,29928,91524,223
Cashflow From Investing-9.1%-5,037.00-4,617.00-5,399.00-3,406.00-2,985.00
Cashflow From Financing-126.2%-397.001,5151,34048,016210,987

Risks

What is the probability of a big loss on ARCT?

100%


Probability that Arcturus Therapeutics Holdings stock will be more than 20% underwater in next one year

98.8%


Probability that Arcturus Therapeutics Holdings stock will be more than 30% underwater in next one year.

91.2%


Probability that Arcturus Therapeutics Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ARCT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcturus Therapeutics Holdings was unfortunately bought at previous high price.

Returns

Cumulative Returns on ARCT

-13.7%


7-Year Cumulative Returns

12.8%


5-Year Cumulative Returns

19.3%


3-Year Cumulative Returns

What are the long-term rolling returns for ARCT?

FIve years rolling returns for Arcturus Therapeutics Holdings.

Which funds bought or sold ARCT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-35,000
438,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-1,000
-
-%
2022-11-15
Balyasny Asset Management LLC
ADDED
3,039.82
4,860,000
5,030,000
0.01%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-12.64
-73,000
338,000
-%
2022-11-15
JANE STREET GROUP, LLC
REDUCED
-15.91
-120,000
461,000
-%
2022-11-15
Laurel Wealth Advisors LLC
SOLD OFF
-100
-2,000
-
-%
2022-11-15
Clearstead Advisors, LLC
UNCHANGED
-
-
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
1,096.77
815,054
894,431
-%
2022-11-15
STATE STREET CORP
REDUCED
-2.72
-3,716,000
40,465,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%

1–10 of 43

Latest Funds Activity

Are funds buying ARCT calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ARCT

Arcturus Therapeutics Holdings News

Stocks Register

An Analysis Of Arcturus Therapeutics Holdings Inc.'s (ARCT) Stock Behavior.29 hours ago

ARCT Fair Value

Recent SEC filings of Arcturus Therapeutics Holdings

View All Filings
Date Filed Form Type Document
Nov 09, 2022
8-K
Current Report
Nov 09, 2022
10-Q
Quarterly Report
Nov 04, 2022
8-K
Current Report
Nov 02, 2022
8-K
Current Report
Sep 01, 2022
8-K
Current Report
Aug 17, 2022
4
Insider Trading

Latest Insider Trading transactions for ARCT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-15
SASSINE ANDY
ACQUIRED
19,672
18.4195
1,068
Chief Financial Officer
2022-01-04
Chivukula Pad
SOLD
-324,000
40
-8,100
Chief Scientific Officer & COO
2021-12-16
Chivukula Pad
SOLD
-145,328
40.0021
-3,633
Chief Scientific Officer & COO
2021-12-08
Chivukula Pad
SOLD
-254,680
40
-6,367
Chief Scientific Officer & COO
2021-11-01
Chivukula Pad
SOLD
-444,100
44.41
-10,000
Chief Scientific Officer & COO
2021-10-01
Chivukula Pad
SOLD
-443,600
44.36
-10,000
Chief Scientific Officer & COO
2021-09-01
Chivukula Pad
SOLD
-558,600
55.86
-10,000
Chief Scientific Officer & COO
2021-08-11
Ultragenyx Pharmaceutical Inc.
SOLD
-3,437,250
45.83
-75,000
-
2021-08-10
Ultragenyx Pharmaceutical Inc.
SOLD
-40,194,000
55.44
-725,000
-
2021-08-03
Chivukula Pad
SOLD
-400,700
40.07
-10,000
Chief Scientific Officer & COO

1–10 of 32

ARCT Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]    
Revenue$ 13,369$ 2,437$ 45,706$ 6,565
Operating expenses:    
Research and development, net37,68845,398120,770141,127
General and administrative12,48810,86034,21130,645
Total operating expenses50,17656,258154,981171,772
Loss from operations(36,807)(53,821)(109,275)(165,207)
Gain (loss) from equity-method investment (250)(515)670
Gain from foreign currency1,8625063,237923
Finance expense, net(321)(519)(1,445)(1,397)
Net loss$ (35,266)$ (54,084)$ (107,998)$ (165,011)
Net loss per share, basic$ (1.33)$ (2.05)$ (4.09)$ (6.27)
Net loss per share, diluted$ (1.33)$ (2.05)$ (4.09)$ (6.27)
Weighted-average shares outstanding, basic26,46726,33826,42326,302
Weighted-average shares outstanding, diluted26,46726,33826,42326,302
Comprehensive loss:    
Net loss$ (35,266)$ (54,084)$ (107,998)$ (165,011)
Comprehensive loss$ (35,266)$ (54,084)$ (107,998)$ (165,011)

ARCT Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 237,676$ 370,492
Accounts receivable2,0443,367
Prepaid expenses and other current assets6,9605,102
Total current assets246,680378,961
Property and equipment, net11,3475,643
Operating lease right-of-use asset, net33,5195,618
Equity-method investment 515
Non-current restricted cash2,0812,077
Total assets293,627392,814
Current liabilities:  
Accounts payable17,96210,058
Accrued liabilities25,52923,523
Current portion of long-term debt27,70222,474
Deferred revenue4,65643,482
Total current liabilities75,84999,537
Deferred revenue, net of current portion5,17919,931
Long-term debt, net of current portion32,03840,633
Operating lease liability, net of current portion31,2184,502
Other non-current liabilities3,676 
Total liabilities147,960164,603
Stockholders’ equity  
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,492 at September 30, 2022 and 26,372 at December 31, 20212626
Additional paid-in capital601,129575,675
Accumulated deficit(455,488)(347,490)
Total stockholders’ equity145,667228,211
Total liabilities and stockholders’ equity$ 293,627$ 392,814